BAT2606 vs Depemokimab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: IL-5 · full Asthma pipeline
BAT2606
Developed by Bio-Thera Solutions
NCT05576454 · Phase 1 · completed
Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Reported efficacy
Cmax (Day1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 22, 29, 43, 57, 71, 85, 99, 113); AUC0-∞ (Day1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 22, 29, 43, 57, 71, 85, 99, 113): In 207 subjects enrolled and randomized, the 90% confidence intervals of the geometric mean ratios of maximum concentration and area under the curve from time 0 to infinity were within 80.00%-125.00%. (met)
Result source: NCT05576454
Depemokimab
Marketed by GlaxoSmithKline
NCT04718389 · Phase 3 · completed
This was a large randomized, double-blind, active-controlled trial comparing depemokimab with mepolizumab or benralizumab, using the clinically meaningful primary endpoint of annualized clinically significant asthma exacerbations. The primary results were 0.57 versus 0.49 exacerbations per participant-year (rate ratio 1.16, 95% CI 0.98–1.38; p=0.079), but the record does not provide the non-inferiority margin, so it is not possible to confirm that the primary endpoint was met.
Next expected readout: February 2027 · NCT07828327 (registry estimate)
Reported efficacy
Annualized Rate of Clinically Significant Exacerbations up to 52 Weeks (Up to Week 52): Annualized Rate of Clinically Significant Exacerbations up to 52 Weeks (Up to Week 52): Placebo 1.11 Exacerbation per participant per year (95% CI 0.86 to 1.43) | GSK3511294 0.46 Exacerbation per participant per year (95% CI 0.36 to 0.58) (met)
Result source: NCT04719832
Results for Asthma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | BAT2606 | Depemokimab |
|---|---|---|
| Severe exacerbations, annualised rate | —Not reported | 0.6 vs 1.1−0.5 vs placeboNCT047181031 other result
|
| Trough FEV1, change | —Not reported | 0.2 vs 0.2+0.1 vs placeboNCT04718103 |
| ACQ-5, change | —Not reported | -0.8 vs -0.7−0.1 vs placeboNCT047181031 other result
|
| OCS dose reduction | —Not reported | —Trial running · NCT06979323 |
Severe exacerbations, annualised rate
- BAT2606
- —Not reported
- Depemokimab
- 0.6 vs 1.1−0.5 vs placeboNCT04718103
1 other result
- 0.5 vs 1.1 NCT04719832
Trough FEV1, change
- BAT2606
- —Not reported
- Depemokimab
- 0.2 vs 0.2+0.1 vs placeboNCT04718103
ACQ-5, change
- BAT2606
- —Not reported
- Depemokimab
- -0.8 vs -0.7−0.1 vs placeboNCT04718103
1 other result
- -0.8 vs -0.8 NCT04719832
OCS dose reduction
- BAT2606
- —Not reported
- Depemokimab
- —Trial running · NCT06979323
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. BAT2606: 0 of 4 rows · Depemokimab: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Depemokimab |
|---|---|
| Dropout rate | 11.2%100mg SCa NCT04718389 · Phase 3 · combination · Asthma · phase 3 show 13 more results11.4% NCT04718103 · Phase 3 · monotherapy · Asthma · phase 3 8.5% NCT04719832 · Phase 3 5.6%100 mg SC NCT05243680 · Phase 3 · registry result, not featured evidence 7%100 mg SC NCT05243680 · Phase 3 · registry result, not featured evidence 1.4%Depemokimab Via Autoinjector NCT05602025 · Phase 1 · registry result, not featured evidence 1.4%Depemokimab Via SSD NCT05602025 · Phase 1 · registry result, not featured evidence 0%100mg NCT05140200 · Phase 1 · registry result, not featured evidence 10%300mg NCT05140200 · Phase 1 · registry result, not featured evidence —100mg NCT03287310 · Phase 1 · registry result, not featured evidence —300mg NCT03287310 · Phase 1 · registry result, not featured evidence —30mg NCT03287310 · Phase 1 · registry result, not featured evidence —10mg NCT03287310 · Phase 1 · registry result, not featured evidence —2mg NCT03287310 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | 0.8%100mg SCa NCT04718389 · Phase 3 · combination · Asthma · phase 3 show 13 more results0.4% NCT04718103 · Phase 3 · monotherapy · Asthma · phase 3 0% NCT04719832 · Phase 3 0.2%100 mg SC NCT05243680 · Phase 3 · registry result, not featured evidence 0.5%100 mg SC NCT05243680 · Phase 3 · registry result, not featured evidence —Depemokimab Via Autoinjector NCT05602025 · Phase 1 · registry result, not featured evidence —Depemokimab Via SSD NCT05602025 · Phase 1 · registry result, not featured evidence —100mg NCT05140200 · Phase 1 · registry result, not featured evidence —300mg NCT05140200 · Phase 1 · registry result, not featured evidence —100mg NCT03287310 · Phase 1 · registry result, not featured evidence —300mg NCT03287310 · Phase 1 · registry result, not featured evidence —30mg NCT03287310 · Phase 1 · registry result, not featured evidence —10mg NCT03287310 · Phase 1 · registry result, not featured evidence —2mg NCT03287310 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 9.4%100mg SCa NCT04718389 · Phase 3 · combination · Asthma · phase 3 show 13 more results7.6% NCT04718103 · Phase 3 · monotherapy · Asthma · phase 3 6% NCT04719832 · Phase 3 9.1%100 mg SC NCT05243680 · Phase 3 · registry result, not featured evidence 10%100 mg SC NCT05243680 · Phase 3 · registry result, not featured evidence 2.9%Depemokimab Via Autoinjector NCT05602025 · Phase 1 · registry result, not featured evidence 0%Depemokimab Via SSD NCT05602025 · Phase 1 · registry result, not featured evidence 0%100mg NCT05140200 · Phase 1 · registry result, not featured evidence 0%300mg NCT05140200 · Phase 1 · registry result, not featured evidence 0%100mg NCT03287310 · Phase 1 · registry result, not featured evidence 0%300mg NCT03287310 · Phase 1 · registry result, not featured evidence 0%30mg NCT03287310 · Phase 1 · registry result, not featured evidence 0%10mg NCT03287310 · Phase 1 · registry result, not featured evidence 0%2mg NCT03287310 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | 100mg SCa nasopharyngitis 20.6% covid-19 18.3% upper respiratory tract infection 11.4% NCT04718389 · Phase 3 · combination · Asthma · phase 3 show 13 more resultscovid-19 14.3% (placebo 14.7%) nasopharyngitis 13.1% (placebo 20.9%) upper respiratory tract infection 8.4% (placebo 4.7%) NCT04718103 · Phase 3 · monotherapy · Asthma · phase 3 covid-19 20.4% (placebo 20.5%) nasopharyngitis 11.6% (placebo 18.9%) upper respiratory tract infection 10% (placebo 10.6%) NCT04719832 · Phase 3 100 mg SC nasopharyngitis 13.8% upper respiratory tract infection 10.7% covid-19 6.7% NCT05243680 · Phase 3 · registry result, not featured evidence 100 mg SC upper respiratory tract infection 11.9% nasopharyngitis 10% covid-19 7.1% NCT05243680 · Phase 3 · registry result, not featured evidence headache 8.6% injection site swelling 5.7% abdominal pain 4.3% NCT05602025 · Phase 1 · registry result, not featured evidence headache 10% injection site bruising 4.3% nausea 4.3% NCT05602025 · Phase 1 · registry result, not featured evidence 100mg blood creatine phosphokinase increased 80% blood uric acid increased 30% neutrophil count increased 20% NCT05140200 · Phase 1 · registry result, not featured evidence 300mg albumin urine present 50% blood creatine phosphokinase increased 40% blood uric acid increased 40% NCT05140200 · Phase 1 · registry result, not featured evidence 100mg nasopharyngitis 55.6% (placebo 16.7%) headache 33.3% (placebo 0%) back pain 22.2% (placebo 8.3%) NCT03287310 · Phase 1 · registry result, not featured evidence 300mg headache 33.3% (placebo 0%) nasopharyngitis 33.3% (placebo 16.7%) epistaxis 16.7% (placebo 0%) NCT03287310 · Phase 1 · registry result, not featured evidence 30mg nasopharyngitis 33.3% (placebo 16.7%) arthropod sting 22.2% (placebo 0%) dry skin 22.2% (placebo 0%) NCT03287310 · Phase 1 · registry result, not featured evidence 10mg dyspepsia 33.3% (placebo 0%) rib fracture 33.3% (placebo 0%) seasonal allergy 33.3% (placebo 16.7%) NCT03287310 · Phase 1 · registry result, not featured evidence 2mg nasopharyngitis 33.3% (placebo 16.7%) diarrhoea 16.7% (placebo 0%) headache 16.7% (placebo 0%) NCT03287310 · Phase 1 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 12 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Depemokimab
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
+ 5 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BAT2606's landscape · Depemokimab's landscape